Bionano Genomics Reports on Shareholder Vote

TL;DR

BNGO had a shareholder vote on Jan 15th, details in new 8-K.

AI Summary

Bionano Genomics, Inc. filed an 8-K on January 16, 2025, reporting on matters submitted to a vote of security holders on January 15, 2025. The filing details the company's corporate actions and governance decisions.

Why It Matters

This filing indicates important corporate governance actions are being taken by Bionano Genomics, which could impact shareholder rights and company direction.

Risk Assessment

Risk Level: low — This is a routine 8-K filing regarding a shareholder vote, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Bionano Genomics, Inc. (company) — Registrant
• January 15, 2025 (date) — Date of earliest event reported
• January 16, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Sto

Filing Documents

• bngo-20250115.htm (8-K) — 29KB
• 0001411690-25-000005.txt ( ) — 149KB
• bngo-20250115.xsd (EX-101.SCH) — 2KB
• bngo-20250115_lab.xml (EX-101.LAB) — 21KB
• bngo-20250115_pre.xml (EX-101.PRE) — 12KB
• bngo-20250115_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On January 15, 2025, Bionano Genomics, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting"). As of November 21, 2024 the record date for the Special Meeting (the "Record Date"), 101,993,225 shares of the Company's common stock were outstanding and entitled to vote at the Special Meeting. A summary of the matters voted upon by stockholders at the Special Meeting is set forth below. A total of 42,460,843 shares of the Company's common stock were present at the Special Meeting in person, by virtual attendance, or by proxy, which represents approximately 41.63% of the shares of the Company's common stock outstanding as of the Record Date. Proposal 1. Approval of the Issuance of Shares of Common Stock Issuable Upon Exercise of Warrants. The Company's stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 19,762,226 shares of common stock issuable upon the exercise of certain Series C warrants and Series D warrants issued in connection with a private placement pursuant to the securities purchase agreement, dated October 30, 2024, among the Company and certain institutional investors party thereto. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,103,569 3,340,296 6,675,748 25,341,230 Proposal 2. Approval of a Series of Alternate Amendments to the Company's Amended and Restated Certificate of Incorporation. The Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company's Board of Directors, a reverse stock split of the Company's common stock at a ratio between 1-for-25 and 1-for-75, inclusive, with the exact ratio to be determined by the Company's Board of Directors in its sole discretion. The final voting results are as follows:

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bionano Genomics, Inc. Date: January 16, 2025 By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR